■本研究旨在确定吡格列酮在糖尿病患者中引起的脉络膜厚度的变化。
■共有261例2型糖尿病患者口服吡格列酮超过6个月被纳入研究。在排除未进行定期眼科检查或在治疗期间进行眼科手术/干预的患者后,共包括40只眼。该研究检查了吡格列酮的持续时间和剂量,患者年龄,眼轴长度,折射,糖化血红蛋白,收缩压,矫正视力,黄斑厚度,脉络膜厚度,和脉络膜血管指数.如果吡格列酮的剂量为每天30mg或更多,则将患者分为高剂量组。和低剂量组,如果它是15mg或更少。脉络膜厚度是在凹下下方测量的,并且在该位置的500µm半径和颞侧测量的。
■在所有受试者中接受吡格列酮治疗6个月和12个月后,脉络膜厚度显着增加(6.70µm,13.65µm,each).当按吡格列酮剂量分层时,脉络膜厚度在6个月和12个月时都增加了(4.48µm,0.84µm,每个)和低剂量组(6.85µm,21.45µm,each),在低剂量组中观察到更大的变化(分别为p<0.05)。根据脉络膜厚度测量的位置,在中心凹下接受吡格列酮治疗6个月和12个月时,脉络膜厚度显着增加(7.00µm,13.15µm,每个)和鼻腔区域(6.43µm,19.24µm,each),而仅在治疗6个月后观察到颞区(8.53µm)显着增加(分别为p<0.05)。在鼻侧观察到脉络膜厚度的最大增加。
■这项研究发现,服用吡格列酮后,糖尿病患者的脉络膜厚度增加。建议使用吡格列酮的糖尿病患者定期进行眼科检查。
UNASSIGNED: This study aimed to determine the changes in choroidal thickness induced by pioglitazone in diabetic patients.
UNASSIGNED: A total of 261 patients diagnosed with type 2 diabetes who had taken oral pioglitazone for more than 6 months were included in the study. After excluding patients who did not undergo regular eye examinations or who had ophthalmic surgery/interventions during the treatment period, a total of 40 eyes were included. The study examined the duration and dosage of pioglitazone, patient age, ocular axial length, refraction, glycated hemoglobin, systolic blood pressure, corrected visual acuity, macular thickness, choroidal thickness, and choroid vascular index. Patients were categorized into a high dose group if their pioglitazone dose was 30mg or more per day, and a low dose group if it was 15mg or less. Choroidal thickness was measured below the subfovea and a 500 µm radius nasal and temporal to that location.
UNASSIGNED: Choroidal thickness significantly increased after 6 and 12 months of pioglitazone in all subjects (6.70µm, 13.65µm, each). When stratified by pioglitazone dosage, choroidal thickness increased at 6 and 12 months in both the high (4.48µm, 0.84µm, each) and low dose groups (6.85µm, 21.45µm, each), with a greater change observed in low dose group (p<0.05, respectively). Based on the location of choroidal thickness measurements, a significant increase in choroidal thickness was observed at 6 and 12 months of pioglitazone treatment in the subfoveal (7.00µm, 13.15µm, each) and nasal regions (6.43µm, 19.24µm, each), while a significant increase was only observed after 6 months of treatment in the temporal region (8.53µm) (p<0.05, respectively). The largest increase in choroidal thickness was observed in the nasal side.
UNASSIGNED: This study found that choroidal thickness increased in diabetic patients after taking pioglitazone. Regular eye examinations are recommended for diabetic patients who are on pioglitazone.